Purpose The purpose of this paper is to identify avenues for future research in mobile supply chain management (mSCM) in the advent of Industry 4.0. Design/methodology/approach A systematic literature review was used to identify, classify, and analyze current knowledge, identify trends, and propose recommendations for future research. Findings Other research fields, such as operations, production, industrial engineering, and computer science, seem to have a head start in research into Industry 4.0. Several avenues are suggested for investigation under an information systems lens. Research limitations/implications Despite the care taken in the systematic literature review, the language (English), the selected keywords, and selected databases represent a natural limitation. Practical implications With Industry 4.0 at the top of the agenda of managers and countries, it is important to identify relevant research avenues. Originality/value A gap between the extant literature on mSCM and new concerns raised by Industry 4.0 is presented, and some research opportunities to close those gaps are proposed.

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3, the most common dominant spinocerebellar ataxia (SCA) worldwide, is caused by over-repetition of a CAG repeat in the ATXN3/MJD1 gene, which translates into a polyglutamine tract within the ataxin-3 protein. There is no treatment for this fatal disorder. Despite evidence of the safety and efficacy of mesenchymal stromal cells (MSCs) in delaying SCA disease progression in exploratory clinical trials, unanticipated regression of patients to the status prior to treatment makes the investigation of causes and solutions urgent and imperative. In the present study, we compared the efficacy of a single intracranial injection with repeated systemic MSC administration in alleviating the MJD phenotype of two strongly severe genetic rodent models. We found that a single MSC transplantation only produces transient effects, whereas periodic administration promotes sustained motor behavior and neuropathology alleviation, suggesting that MSC therapies should be re-designed to get sustained beneficial results in clinical practice. Furthermore, MSC promoted neuroprotection, increased the levels of GABA and glutamate, and decreased the levels of Myo-inositol, which correlated with motor improvements, indicating that these metabolites may serve as valid neurospectroscopic biomarkers of disease and treatment. This study makes important contributions to the design of new clinical approaches for MJD and other SCAs/polyglutamine disorders.

No abstract

No abstract